EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evaluating the Effect of Alzheimer's Disease‐Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy

Indira Garcia-Cordero iD, Chloe Anastassiadis, Abeer Khoja, Alonso Morales-Rivero, Simrika Thapa, Anna Vasilevskaya, Carly Davenport, Vishaal Sumra iD, Blas Couto, Namita Multani, Foad Taghdiri iD, Cassandra Anor und 17 weitere

Annals of Neurology · 2024

DOI: 10.1002/ana.26930 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, 2024. Verfasst von Indira Garcia-Cordero und 28 weiteren Autor:innen. Beteiligte Einrichtung: Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Supranuclear Palsy, Progressive, Alzheimer Disease, Biomarkers. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, CIHR, Association for Frontotemporal Degeneration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the effect of Alzheimer's disease (AD) ‐related biomarker change on clinical features, brain atrophy and functional connectivity of patients with corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP).

Methods

Data from patients with a clinical diagnosis of CBS, PSP, and AD and healthy controls were obtained from the 4‐R‐Tauopathy Neuroimaging Initiative 1 and 2, the Alzheimer's Disease Neuroimaging Initiative, and a local cohort from the Toronto Western Hospital. Patients with CBS and PSP were divided into AD‐positive (CBS/PSP‐AD) and AD‐negative (CBS/PSP‐noAD) groups based on fluid biomarkers and amyloid PET scans. Cognitive, motor, and depression scores; AD fluid biomarkers (cerebrospinal p‐tau, t‐tau, and amyloid‐beta, and plasma ptau‐217); and neuroimaging data (amyloid PET, MRI and fMRI) were collected. Clinical features, whole‐brain gray matter volume and functional networks connectivity were compared across groups.

Results

Data were analyzed from 87 CBS/PSP‐noAD and 23 CBS/PSP‐AD, 18 AD, and 30 healthy controls. CBS/PSP‐noAD showed worse performance in comparison to CBS/PSP‐AD in the PSPRS [mean(SD): 34.8(15.8) vs 23.3(11.6)] and the UPDRS scores [mean(SD): 34.2(17.0) vs 21.8(13.3)]. CBS/PSP‐AD demonstrated atrophy in AD signature areas and brainstem, while CBS/PSP‐noAD patients displayed atrophy in frontal and temporal areas, globus pallidus, and brainstem compared to healthy controls. The default mode network showed greatest disconnection in CBS/PSP‐AD compared with CBS/PSP‐no AD and controls. The thalamic network connectivity was most affected in CBS/PSP‐noAD.

Interpretation

AD biomarker positivity may modulate the clinical presentation of CBS/PSP, with evidence of distinctive structural and functional brain changes associated with the AD pathology/co‐pathology. ANN NEUROL 2024;96:99–109

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Supranuclear Palsy, ProgressiveAlzheimer DiseaseBiomarkersHumansFemaleMaleAgedMiddle Agedtau ProteinsPositron-Emission TomographyMagnetic Resonance ImagingAmyloid beta-PeptidesCorticobasal DegenerationAtrophyBrain

Substanzen

Biomarkerstau ProteinsAmyloid beta-Peptides

Autor:innen und Institutionen

  • Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
  • University Health Network Memory Clinic, Toronto, ON, Canada.
  • Neurology Division, Medical Department, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
  • ABC Medical Center, Mexico City, Mexico.
  • Rossy PSP Program, University Health Network and the University of Toronto, Toronto, ON, Canada.
  • The Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto, ON, Canada.

ORCID-Profile: Indira Garcia-Cordero, Vishaal Sumra, Foad Taghdiri, M Carmela Tartaglia

Förderung

  • NIA NIH HHS
  • CIHR
  • Association for Frontotemporal Degeneration
  • Alzheimer's Association
  • NIMH NIH HHS
  • Alzheimer's Society of Canada
  • CLC NIH HHS
  • Canadian Institutes of Health Research

Zitieren

APA

Garcia-Cordero, I., Anastassiadis, C., Khoja, A., Morales-Rivero, A., Thapa, S., Vasilevskaya, A., Davenport, C., Sumra, V., Couto, B., Multani, N., Taghdiri, F., Anor, C., Misquitta, K., Vandevrede, L., Heuer, H., Tang-Wai, D., Dickerson, B., Pantelyat, A., Litvan, I., …, & 4‐R‐Tauopathy Neuroimaging Initiative Consortium, and the Alzheimer's Disease Neuroimaging Initiative (2024). Evaluating the Effect of Alzheimer's Disease‐Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy. Annals of Neurology. https://doi.org/10.1002/ana.26930

Vancouver

Garcia-Cordero I, Anastassiadis C, Khoja A, Morales-Rivero A, Thapa S, Vasilevskaya A, et al. Evaluating the Effect of Alzheimer's Disease‐Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy. Annals of Neurology. 2024. doi:10.1002/ana.26930

BibTeX
@article{GarciaCordero2024,
  author = {Garcia-Cordero, Indira and Anastassiadis, Chloe and Khoja, Abeer and Morales-Rivero, Alonso and Thapa, Simrika and Vasilevskaya, Anna and Davenport, Carly and Sumra, Vishaal and Couto, Blas and Multani, Namita and Taghdiri, Foad and Anor, Cassandra and Misquitta, Karen and Vandevrede, Lawren and Heuer, Hilary and Tang-Wai, David and Dickerson, Bradford and Pantelyat, Alexander and Litvan, Irene and Boeve, Bradley and Rojas, Julio C and Ljubenkov, Peter and Huey, Edward and Fox, Susan and Kovacs, Gabor G and Boxer, Adam and Lang, Anthony and Tartaglia, M Carmela and 4‐R‐Tauopathy Neuroimaging Initiative Consortium, and the Alzheimer's Disease Neuroimaging Initiative, 4‐R‐Tauopathy Neuroimaging Initiative Consortium, and the Alzheimer's Disease Neuroimaging Initiative},
  title = {Evaluating the Effect of Alzheimer's Disease‐Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy},
  journal = {Annals of Neurology},
  year = {2024},
  doi = {10.1002/ana.26930}
}
Kostenlos starten →